Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03798639
Title Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hiral Shah
Indications

Merkel cell carcinoma

Therapies

Ipilimumab + Nivolumab

Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.